お知らせ • May 20
Paxman AB (publ) to Report Q1, 2026 Results on May 21, 2026 Paxman AB (publ) announced that they will report Q1, 2026 results at 7:00 AM, Central European Standard Time on May 21, 2026 お知らせ • Apr 21
Paxman AB (publ), Annual General Meeting, May 22, 2026 Paxman AB (publ), Annual General Meeting, May 22, 2026, at 10:00 W. Europe Standard Time. Location: minnesota conference venue, pirgatan 6, 374 35 karlshamn, sweden, Sweden お知らせ • Feb 23
Paxman AB (publ) to Report Fiscal Year 2025 Results on Feb 27, 2026 Paxman AB (publ) announced that they will report fiscal year 2025 results at 7:00 AM, Central European Standard Time on Feb 27, 2026 お知らせ • Feb 21
Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy Paxman announced that the American Medical Association (AMA) CPT Editorial Panel has established three Category III CPT®? codes describing the use of the Paxman Cryocompression Device for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in hands and feet. Taking effect January 1, 2027, the new Category III codes establish a standardized reporting pathway for mechanical extremity cryocompression therapy delivered in conjunction with neurotoxic chemotherapy: The three-code structure mirrors the established coding framework for Paxman's FDA-cleared scalp cooling system, supporting structured reporting, data collection, and payer engagement. During chemotherapy infusion, The Paxman Neuropathy System combines consistent cooling and dynamic compression to the hands and feet to reduce the incidence and severity of CIPN - a common side effect of widely used chemotherapies such as paclitaxel and docetaxel, that can significantly impair patients' quality of life. In October, The Paxman Neuropathy system was accepted into the U.S. Food and Drug Administration Safer Technologies Program (STeP), a voluntary program designed to facilitate development and review of medical devices expected to improve safety outcomes. The device is currently under substantive review by the FDA. Product launches in select markets are planned for 2026, with launch to all markets anticipated in 2027. Clinical development of The Paxman Neuropathy System is supported by strong and expanding evidence, including ongoing clinical trials conducted by the SWOG Cancer Research Network, Dana-Farber Cancer Institute, and the National University Hospital Singapore. Together, these studies are contributing to a growing global evidence base evaluating the safety and effectiveness of cryocompression therapy in preventing CIPN. お知らせ • Jan 02
Paxman Announces 510k Submission to the U.S. Food and Drug Administration for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral Neuropathy PAXMAN announced that the U.S. Food and Drug Administration (FDA) has confirmed receipt of the 510k Submission for the Paxman cryocompression device to prevent chemotherapy-induced peripheral neuropathy (CIPN). A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective. This follows the news in October, that the Paxman device, was accepted into the US FDA's Safer Technologies Program (STeP), and additionally, confirmation that the Category III CPT Code Application for the device, submitted to the American Medical Association (AMA) in November, is to be included on the Proposed Agenda for the February 2026 CPT®? Editorial Panel Meeting. These steps mark significant milestones in Paxman's regulatory pathways towards FDA clearance of this new technology. Product launches in select markets are currently being planned for 2026 with launch to all markets anticipated in 2027. More information regarding timelines will be communicated in the New Year. お知らせ • Oct 20
PAXMAN Announces Acceptance of Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program PAXMAN announced that the U.S. Food and Drug Administration (FDA) has accepted the Paxman Limb Cryocompression System (PLCS) into the FDA's Safer Technologies Program (STeP). The FDA's Safer Technologies Program ("STeP") is a voluntary initiative designed to accelerate the development and clearance of medical devices that have the potential to reduce known risks associated with current treatments for non-life threatening conditions. Paxman submitted the STeP Designation Request Q240974/S002 in August 2025. Confirmation that the PLCS meets the eligibility factors for STeP is a significant milestone in Paxman's regulatory pathways towards FDA clearance of this new technology. Chemotherapy-induced peripheral neuropathy (CIPN) is a severe dose-limiting toxicity of paclitaxel and docetaxel, which are both widely used drugs for the treatment of common cancers including breast, ovarian, endometrial, lung, and gastric cancers. CIPN is an unseen, debilitating, and lifelong condition that severely impacts the quality of life of cancer patients. Acceptance into STeP underscores the innovative potential of the Paxman device to address this important unmet clinical need of reducing the incidence and severity of CIPN in cancer patients receiving systemic neurotoxic chemotherapy or combination therapy. お知らせ • Apr 17
Paxman AB (publ), Annual General Meeting, May 16, 2025 Paxman AB (publ), Annual General Meeting, May 16, 2025, at 10:00 W. Europe Standard Time. Location: at meeting hall zambesi, netport, biblioteksgatan 4, karlshamn, Sweden お知らせ • Apr 08
Paxman AB (Publ) Elects Peter Mattisson as Chairman Paxman AB (publ) announced that Company held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman. お知らせ • Mar 22
Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million. Paxman AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 123.5 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,900,000
Price\Range: SEK 65
Transaction Features: Subsequent Direct Listing お知らせ • Mar 21
Paxman AB (publ) has filed a Follow-on Equity Offering. Paxman AB (publ) has filed a Follow-on Equity Offering.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,900,000
Transaction Features: Subsequent Direct Listing お知らせ • Mar 19
Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc and others for Approximately SEK 150 million. Paxman AB (publ) (OM:PAX) proposed to acquire Dignitana AB (publ) (OM:DIGN) from Agartha AB, UBS Financial Services Inc. and others for Approximately SEK 150 million on March 18, 2025. As part of acquisition, Paxman AB will acquire all shares in Dignitana AB. As part of consideration, Paxman AB will issue 2.5 million newly issued shares at a ratio of 0.030744 per common equity of Dignitana AB (publ). The merger between Paxman and Dignitana creates a New Group which provides clear synergies through increased revenues and reduced costs through rationalization but also economies of scale. Upon completion of the Offer, the shareholders of Paxman will own approximately 88.5% of the votes and capital and the shareholders of Dignitana will own approximately 11.5% of the votes and capital of the New Group. Agartha AB, which controls approximately 29.8% of the total number of outstanding shares and votes in Dignitana, supports and has undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or around April 14, 2025 and end on or around May 5, 2025, with payment of consideration expected to be made on or around May 13, 2025. In the event that Paxman, in connection with the Offer or otherwise, becomes the owner of shares corresponding to more than 90% of the shares in Dignitana, Paxman intends to call for compulsory acquisition in accordance with the Swedish Companies Act (2005:551) in order to acquire all outstanding shares in Dignitana. In connection therewith, Paxman intends to promote the delisting of Dignitana's shares from Nasdaq First North.
The transaction is subject to Offer being accepted to the extent that Paxman becomes the owner of the equivalent of more than 90% of all outstanding shares in Dignitana, approval of the shareholders of Paxman at the extraordinary general meeting of Paxman AB, all necessary authorizations, approvals, decisions and other measures for the Offer and the acquisition of Dignitana are obtained on terms acceptable to Paxman, including approvals from the Inspectorate of Strategic Products and the corresponding authorities in the United Kingdom and Italy. The Offer has been preceded by Paxman conducting a limited due diligence review of Dignitana of a confirmatory nature. The expected completion of the transaction is May 5, 2025.
Advokatfirman Delphi KB acted as legal advisor to Paxman AB. Bergs Securities AB acted as financial advisor and issuing agent to Paxman AB. Advokatfirman Vinge KB act as legal advisor to Dignitana AB. Stockholm Corporate Finance AB act as financial advisor to Dignitana AB. お知らせ • May 24
Paxman AB (publ) Appoints Karen Giddings Clakely to the Board PAXMAN´s AGM held on 23 May 2024, appointed Karen Giddings Clakely to the board. お知らせ • Jan 04
Paxman AB (publ) to Report Fiscal Year 2022 Results on May 04, 2023 Paxman AB (publ) announced that they will report fiscal year 2022 results on May 04, 2023 
